Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240736 | 0.92 | LTC4S (0.59) | LTC4S | |
| SCHEMBL559486 | 0.92 | LTC4S (0.43) | LTC4S | |
| SCHEMBL2755497 | 0.87 | LTC4S (0.56) | LTC4S | |
| SCHEMBL238391 | 0.85 | LTC4S (0.55) | LTC4S | |
| SCHEMBL559628 | 0.83 | LTC4S (0.47) | LTC4S | |
| SCHEMBL236561 | 0.80 | LTC4S (0.73) | LTC4S | |
| SCHEMBL2755502 | 0.79 | LTC4S (0.60) | LTC4S | |
| SCHEMBL560196 | 0.79 | LTC4S (0.47) | LTC4S | |
| SCHEMBL240004 | 0.78 | LTC4S (0.46) | LTC4S | |
| SCHEMBL238185 | 0.78 | LTC4S (0.61) | LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197495-A2 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MDRNA, Inc. (US) | 2010-06-23 | — | — | EP | claimed |
| EP-2157982-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, Inc. (US) | 2010-03-03 | — | — | EP | claimed |
| WO-2009046220-A2 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MDRNA, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2008137758-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| CN-105612217-B | Crosslinking composition having excellent storage stability | 株式会社大阪曹达 | 2018-05-22 | — | — | CN | disclosed |
| CN-107207983-A | Use of a lubricating composition | 国际壳牌研究有限公司 | 2017-09-26 | — | — | CN | disclosed |
| EP-2785178-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081642-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| EP-2443087-A1 | DISUBSTITUTED-AMINODIFLUOROSULFINIUM SALTS, PROCESS FOR PREPARING SAME AND METHOD OF USE AS DEOXOFLUORINATION REAGENTS | Omegachem Inc. (CA) | 2012-04-25 | — | — | EP | disclosed |
| EP-2429994-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-02-09 | — | — | US | disclosed |
| EP-2406220-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2300456-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2296711-A2 | MULTI-ARM AMINES AND USES THEREOF | MDRNA, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010145037-A1 | DISUBSTITUTED-AMINODIFLUOROSULFINIUM SALTS, PROCESS FOR PREPARING SAME AND METHOD OF USE AS DEOXOFLUORINATION REAGENTS | OMEGACHEM INC. (CA) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010103283-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
| EP-2157982-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, Inc. (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009148955-A2 | MULTI-ARM AMINES AND USES THEREOF | MDRNA, INC (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2008137758-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-0202697-B1 | SEPARATION PROCESS FOR PARA-FLUORO-ANILINE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.